Exhibit 99.1
Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update
FYARRO® (nab-sirolimus) net product sales reached $3.4 million for the second quarter of 2022
PRECISION 1 Phase 2 tumor-agnostic registration-directed trial continues enrollment and rapid site activation at major cancer centers and large community networks; preliminary data expected 1H23
Conference call to be held today at 8:30 am EDT
LOS ANGELES, CA, August 10, 2022 – Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2022.
“We continue to progress in key areas after our first full quarter following FYARRO’s launch. We are excited to see FYARRO reaching more patients through continued account adoption and steady growth in overall sales,” said Neil Desai, Ph.D., Founder, President and Chief Executive Officer of Aadi. “We are also encouraged by the progress on our tumor agnostic PRECISION 1 trial targeting TSC1 and TSC2 inactivating alterations which continues to ramp up, with activation of additional clinical trial sites and patient enrollment. We anticipate providing preliminary data on a meaningful number of patients in this trial during the first half of 2023. In addition, we continue to evaluate strategies for new clinical indications of nab-sirolimus either as single agent or in combination with other targeted therapies with the potential for new programs as early as 2023.”
Corporate Updates for the Second Quarter 2022
| • | FYARRO net product sales for the three months ended June 30, 2022 were $3.4 million, the first full quarter of sales following the product launch late in the first quarter. |
| • | A product-specific permanent J-code (J9331) for FYARRO from Centers for Medicare and Medicaid Services (CMS) became effective on July 1, 2022. This code is expected to further facilitate reimbursement for FYARRO. |
| • | The Company announced its addition to both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, which captures the 4,000 largest U.S. stocks, ranking them by total market capitalization. |
| • | Partnerships with prominent next generation sequencing (NGS) providers and leaders in genomic testing and profiling was announced during the quarter, which included Foundation Medicine, Tempus and others. The Company is leveraging these partnerships to expedite patient identification and recruitment for the ongoing PRECISION 1 trial of nab-sirolimus in patients harboring tumors with inactivating alterations in TSC1 or TSC2 genes, and is making significant progress toward opening the trial in at least 20 major cancer centers and upward of 120 treatment sites in the U.S. by the end of 2022. |
| • | A poster presentation entitled, “nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program” was presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The data included exploratory biomarker results reported from the final analysis of mTOR inhibitor-naïve advanced malignant PEComa patients treated with nab-sirolimus in the Advanced Malignant PEComa Trial (AMPECT) trial as well as an analysis of prior mTOR inhibitor exposed advanced malignant PEComa patients treated with nab-sirolimus in the Expanded Access Program (EAP) through June 2021. Findings from both the AMPECT study and the EAP showed greater clinical benefit in patients with TSC1 or TSC2 inactivating alterations who received nab-sirolimus compared to all evaluable patients, regardless of prior mTOR inhibitor exposure. |
| • | The Company sponsored a poster at the Annual Meeting of the American Association for Cancer Research (AACR) which indicated the incidence of advanced cancer patients carrying TSC1 or TSC2 inactivating gene alterations numbered approximately 12,000 annually in the US, thus potentially rendering these patients eligible for nab-sirolimus therapy. |
Second Quarter 2022 Financial Results
| • | Cash and cash equivalents on June 30, 2022 were $118.7 million, compared to $149.0 million as of December 31, 2021. Based on current plans, the Company expects cash and cash equivalents to fund operations into 2024. |
| • | Total revenue for the quarter ended June 30, 2022 was $3.4 million resulting from sales of FYARRO. |
| • | In the second quarter of 2022, the Company recorded a non-cash impairment charge of $3.7 million to write-off the value of an intangible asset related to the Gossamer license agreement with the Company’s predecessor, Aerpio. |
| • | Net loss for the three months ended June 30, 2022 was $18.3 million compared to $1.5 million for the three months ended June 30, 2021. |
Conference Call Information
The Aadi management team is hosting a conference call and webcast today at 8:30 am ET (5:30 am PT) to provide a corporate update and discuss results for the second quarter of 2022.
Participants may access a live webcast of the call on the “Investors & News” page of the Aadi Biosciences website at aadibio.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About FYARRO®
FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
About the PRECISION 1 Trial
The PRECISION 1 trial is a multi-center, open-label, tumor-agnostic pivotal study, of nab-sirolimus designed as a basket trial that will evaluate approximately 120 adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. The trial will have two independent arms of 60 patients each to separately evaluate patients with either TSC1 or TSC2 inactivating alterations. Aadi has received Fast Track designation to evaluate nab-sirolimus in this indication from the FDA. The first patient in the PRECISION 1 trial was dosed in March 2022.
About Aadi Bioscience
Aadi is a biopharmaceutical company focused on precision therapies for genetically defined cancers. Aadi’s primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. In November 2021, Aadi received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), and in February 2022 Aadi announced the commercial launch of FYARRO in this indication.
Based on exploratory data from AMPECT, Aadi’s registrational study supporting approval in malignant PEComa, and following a pre-IND meeting with the FDA, Aadi has initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on Aadi’s development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the business of Aadi Biosciences that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s current beliefs and expectations; plans and potential for success relating to commercializing FYARRO; expectations regarding the beneficial characteristics, safety, efficacy and therapeutic effects of FYARRO; plans related to further development and manufacturing of FYARRO; pricing and reimbursement of FYARRO; the rate and degree of market acceptance of FYARRO; anticipated reception of FYARRO in the physician community; the clinical results and timing of additional clinical trials, including the registration-directed trial in patients harboring TSC1 or TSC2 inactivating alterations; the timing and likelihood of regulatory filings and approvals of FYARRO, including in potential additional indications and potential filings in additional jurisdictions; and the sufficiency of our existing capital resources and the expected timeframe to fund our future operating expenses and capital expenditure requirements. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, those associated with the
ability to successfully commercialize FYARRO; risks related to reimbursement and pricing of FYARRO; uncertainties associated with the clinical development and regulatory approval of FYARRO in additional indications, including potential delays in the commencement, enrollment and completion of clinical trials for additional indications; the risk that unforeseen adverse reactions or side effects may occur in the course of commercializing, developing and testing FYARRO; risks associated with the failure to realize any value from FYARRO in light of inherent risks and difficulties involved in successfully bringing product candidates to market; risks related to Aadi’s estimates regarding future expenses, capital requirements and need for additional financing; and risks related to the impact of the COVID-19 pandemic on Aadi’s operations, the biotechnology industry and the economy generally.
Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, including under the caption “Item 1. Risk Factors” and in Aadi’s subsequent Quarterly Reports on Form 10-Q filed on May 12, 2022 and August 10, 2022, and elsewhere in Aadi’s reports and other documents that Aadi has filed, or will file, with the SEC from time to time and available at www.sec.gov.
All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Aadi undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Marcy Graham
IR@aadibio.com
AADI BIOSCIENCE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 118,737 | $ | 148,989 | ||||
| Accounts receivable, net |
2,063 | — | ||||||
| Inventory |
727 | — | ||||||
| Prepaid expenses and other current assets |
2,808 | 2,283 | ||||||
|
|
|
|
|
|||||
| Total current assets |
124,335 | 151,272 | ||||||
| Property and equipment, net |
357 | 57 | ||||||
|
Operating lease right-of-use assets |
1,653 | 557 | ||||||
| Intangible asset, net |
— | 3,811 | ||||||
| Other assets |
2,291 | 2,213 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 128,636 | $ | 157,910 | ||||
|
|
|
|
|
|||||
| Liabilities and stockholders’ equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 3,619 | $ | 6,439 | ||||
| Accrued liabilities |
8,653 | 8,703 | ||||||
| Operating lease liabilities, current portion |
324 | 131 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
12,596 | 15,273 | ||||||
| Other liabilities |
109 | — | ||||||
| Operating lease liabilities, net of current portion |
1,444 | 474 | ||||||
| Due to licensor |
5,757 | 5,757 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
19,906 | 21,504 | ||||||
| Stockholders’ equity: |
||||||||
| Preferred stock |
— | — | ||||||
| Common stock |
2 | 2 | ||||||
| Additional paid-in capital |
283,539 | 279,089 | ||||||
| Accumulated deficit |
(174,811 | ) | (142,685 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
108,730 | 136,406 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 128,636 | $ | 157,910 | ||||
|
|
|
|
|
|||||
AADI BIOSCIENCE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except shares and earnings per share amounts)
(Unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue |
||||||||||||||||
| Product sales, net |
$ | 3,437 | $ | — | $ | 5,744 | $ | — | ||||||||
| Grant revenue |
— | 120 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total Revenue |
3,437 | — | 5,744 | 120 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating expenses |
||||||||||||||||
| Selling, general and administrative |
10,006 | 830 | 19,154 | 1,393 | ||||||||||||
| Research and development |
7,726 | 3,045 | 14,519 | 6,689 | ||||||||||||
| Cost of goods sold |
341 | — | 520 | — | ||||||||||||
| Impairment of intangible asset |
3,724 | — | 3,724 | — | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
21,797 | 3,875 | 37,917 | 8,082 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss from operations |
(18,360 | ) | (3,875 | ) | (32,173 | ) | (7,962 | ) | ||||||||
| Other income (expense) |
||||||||||||||||
| Change in fair value of convertible promissory notes |
— | 2,371 | — | 1,206 | ||||||||||||
| Gain upon extinguishment of debt |
— | 196 | — | 196 | ||||||||||||
| Interest income |
158 | 1 | 171 | 1 | ||||||||||||
| Interest expense |
(58 | ) | (227 | ) | (115 | ) | (451 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other income, net |
100 | 2,341 | 56 | 952 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income tax expense |
(18,260 | ) | (1,534 | ) | (32,117 | ) | (7,010 | ) | ||||||||
| Income tax expense |
(9 | ) | (2 | ) | (9 | ) | (2 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss |
$ | (18,269 | ) | $ | (1,536 | ) | $ | (32,126 | ) | $ | (7,012 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss per share attributable to common stockholders, basic and diluted |
$ | (0.87 | ) | $ | (0.60 | ) | $ | (1.53 | ) | $ | (2.76 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average number of common shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted |
20,970,459 | 2,542,358 | 20,942,804 | 2,542,358 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
###